Cc workflow
Skill brycewang-stanford/Awesome-Journal-Skills/Cancer-Cell-Skills/skills/cc-workflow
Journal-specific Claude Code/Codex skill packs covering mainstream journals — AER, QJE, Nature, Cell, 管理世界, 经济研究 & 200+ more — your fast track to getting published. | 覆盖主流期刊的 Claude Code/Codex 期刊技能包,从选题、识别策略到表格规范与审稿回复全流程,助你快速发论文。
npx -y skills add brycewang-stanford/Awesome-Journal-Skills --skill cc-workflowAssembled from the repository path, not quoted from the project. Check it against their README if it does not work.
What its author says it does
Copied from the file, not written here
Use when deciding which cc-* sub-skill to invoke next, or when sequencing a Cancer Cell (Cell Press) manuscript from scope check through peer-review revision. Routes — it does not replace — the specialized skills.
SKILL.md
7.7 KB, ~1.8k tokens by cl100k_base, as published. Nobody here has run it
Cancer Cell Workflow (cc-workflow)
Overview
This is the router. It does not replace any specialized skill — it tells you which cc- skill to use at your current stage* of a Cancer Cell (Cell Press) molecular / translational oncology manuscript.
Default assumption: unless the user says otherwise, treat the target as Cancer Cell, where the bar is a clear molecular mechanism validated across orthogonal systems (cells + in vivo + ideally human data), reported with STAR Methods rigor, framed for translational relevance without overclaiming.
When to trigger
- The user asks "what should I do next?"
- A draft arrives and you must diagnose the current bottleneck
- Work is thrashing between experiments, figures, and writing
- A decision letter / reviewer reports arrive and you must switch into revision mode
Routing table
| Current symptom | Next skill |
|---|---|
| Unsure whether the story is a Cancer Cell paper at all | cc-scope-fit |
| Mechanism rests on one system (cells only / no in vivo / no human data) | cc-study-design |
| Controls, replicates, randomization, or blinding are unclear | cc-study-design |
| No Key Resources Table; cell lines unauthenticated; antibodies unvalidated | cc-reporting-standards |
n undefined, pseudo-replication risk, wrong test, error bars unlabeled | cc-statistics |
| Representative images with no quantification; multi-panel figure messy | cc-figures-tables |
| Need Summary / Highlights / eTOC blurb / graphical abstract | cc-structured-abstract |
| Missing IACUC/IRB approval, consent, biosafety, or data-availability statement | cc-ethics-registration |
| Prose overclaims; Results read like a lab notebook; weak Discussion | cc-writing-style |
| Need a cover letter framing fit and significance | cc-cover-letter |
| About to submit and need a final preflight | cc-submission |
| Reviewer reports arrived; need a point-by-point response | cc-peer-review-revision |
Default order
cc-scope-fit— confirm mechanism + translational relevance before investing morecc-study-design— design / audit orthogonal validation, controls, replicates, in vivo rigorcc-reporting-standards— STAR Methods, Key Resources Table, authentication, RRIDscc-statistics— definen, pick tests, correct for multiplicity, label error barscc-figures-tables— multi-panel mechanistic figures with quantification + image integritycc-structured-abstract— Summary, Highlights, eTOC blurb, graphical abstractcc-ethics-registration— approvals, consent, biosafety, data-deposition statementscc-writing-style— Cell Press prose and claim calibration (polish stage)cc-cover-letter— significance / fit / suggested reviewerscc-submission— pre-submission preflightcc-peer-review-revision— after reviewer reports
cc-writing-styleandcc-structured-abstractare late-stage polish — do not finalize them while the mechanism or in vivo validation is still missing.
Decision shortcuts
- "It's only in cell lines" →
cc-study-design(add in vivo / human validation) - "Reviewers will ask if the cell line is authenticated" →
cc-reporting-standards - "I used n=3 wells from one experiment" →
cc-statistics(pseudo-replication) - "I have a beautiful blot but no densitometry" →
cc-figures-tables - "My title promises a therapy but I have no in vivo efficacy" →
cc-scope-fitthencc-writing-style - "No GEO accession yet" →
cc-ethics-registration/cc-submission - "Three reviewers, consultative cross-review" →
cc-peer-review-revision
Differences vs. JAMA-style clinical packs
If the work is a clinical trial or epidemiological cohort with patient-level outcomes as the core unit, a clinical-trial pack (CONSORT / STROBE / registration) fits better. Cancer Cell's unit is a mechanism validated across systems, not a trial endpoint.
Worked routing example
"We have RNA-seq showing MARK7 correlates with CAF activation in a patient cohort, plus a knockdown migration phenotype in one PDAC line. We want to submit to Cancer Cell."
Route it:
cc-scope-fit— a correlation + single-line phenotype is off-fit on both pillars; the mechanism is not established and there is no in vivo/orthogonal validation. Gate here first.cc-study-design— plan the missing spine: in vivo perturbation in an immunocompetent model, a second cell system, and a mechanistic intermediate linking MARK7 to the phenotype.- Only once that evidence exists do
cc-reporting-standards→cc-statistics→cc-figures-tablesapply; drafting front matter (cc-structured-abstract,cc-writing-style) before then is premature.
The router's job is to stop a promising-but-thin story from being polished into a confident desk reject.
Stage diagnosis cues
| What the user says | Likely stage | Route |
|---|---|---|
| "Is this even a Cancer Cell paper?" | Pre-scope | cc-scope-fit |
| "Reviewers will ask about in vivo" | Design gap | cc-study-design |
| "My Methods feel thin" | Reporting | cc-reporting-standards |
| "Is n=3 wells enough?" | Statistics | cc-statistics |
| "The blot has no quantification" | Display | cc-figures-tables |
| "The Summary buries the finding" | Front matter | cc-structured-abstract |
| "I have no GEO accession" | Ethics/deposition | cc-ethics-registration |
| "Final check before upload" | Preflight | cc-submission |
| "Three reviewers came back" | Revision | cc-peer-review-revision |
Evidence-spine manifest
Cancer Cell's unit is a mechanism validated across orthogonal systems. Track the spine as a
manifest and route on the first MISSING: front-matter polish is premature until cells +
in vivo + (ideally) human evidence converge on one mechanism.
evidence_spine:
mechanism: OK | UNCLEAR # molecular intermediate linking cause -> phenotype
cell_system_1: OK | MISSING
cell_system_2: OK | MISSING # orthogonal line / method, not a technical replicate
in_vivo: OK | MISSING # perturbation in an immunocompetent model
human_data: OK | MISSING # patient cohort / clinical specimens
rigor:
key_resources_table: yes | no # cc-reporting-standards
cell_line_authenticated: yes | no
n_defined_no_pseudorep: yes | no # cc-statistics
image_quantification: yes | no # cc-figures-tables
deposition:
geo_or_pride_accession: yes | no # cc-ethics-registration
route_rule: "first MISSING/UNCLEAR above -> its listed skill; do not draft Summary/Highlights until the spine is OK"
Anti-patterns
- Do not skip
cc-scope-fit— editors triage on mechanism + translational fit first - Do not let
cc-figures-tablespolish panels beforecc-statisticshas fixednand tests - Do not let
cc-peer-review-revisiondraft a response before the revised experiments / text exist - Do not route to front-matter polish while the in vivo or human-validation spine is still missing
- Do not treat a presubmission inquiry as a substitute for the scope gate — run
cc-scope-fitregardless
What ships with it
Read from the repository
Just SKILL.md. No reference files, no scripts.